Comparative outcomes of proton and photon therapy in the management of malignant peripheral nerve sheath tumors
European Spine Journal · 07.07.2026
DOI: 10.1007/s00586-026-10185-y ↗Kurz gefasst
Fachartikel in der Zeitschrift European Spine Journal, online erschienen am 07.07.2026. Verfasst von Taha Khalilullah und 19 weiteren Autor:innen. Beteiligte Einrichtung: Johns Hopkins University, Baltimore, USA. Die Arbeit nennt 31 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Malignant Peripheral Nerve Sheath Tumors (MPNSTs) are aggressive sarcomas often arising in the spine, characterized by high metastatic potential and poor prognosis. While photon radiation therapy (RT) has been employed for local control, the role of proton RT in spinal MPNST remains poorly defined. Our objective is to compare treatment patterns, survival outcomes, and predictors of mortality among spinal MPNST patients treated with photon vs. proton RT. METHODS: This retrospective cohort study utilized the National Cancer Database (2004-2017) to identify patients with spinal MPNST. Demographics, tumor characteristics, treatment details, and outcomes were compared between patients receiving no radiation, photon RT, or proton RT. Survival was assessed using Kaplan-Meier analysis and Cox proportional hazards models. Machine learning-based survival models evaluated predictive performance, feature importance, and SHAP values. RESULTS: Of 5,664 spinal MPNST patients, 3,264 (57.3%) received RT (photon: 97.5%; proton: 2.5%). Proton therapy recipients were younger, had smaller tumors, and more frequently received adjuvant chemoradiation (p 70 Gy) were predictors of both short- and long-term mortality on the multivariate model. The Gradient Boosting model identified BED, CDCC score, and tumor size as the most influential predictors, with a highest AUC for 10-year mortality of 0.715. CONCLUSION: Proton therapy is associated with superior long-term survival compared to photon therapy in spinal MPNST patients, particularly among the subtotal resection cohort. Radiation dose, tumor size, and comorbidity burden are strong predictors of mortality. These findings support the integration of proton therapy into treatment algorithms and emphasize the importance of individualized, risk-adapted strategies to improve survival in patients with spinal MPNST.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Johns Hopkins University, Baltimore, USA.
- Johns Hopkins University, Baltimore, USA. abdulkarimghaith@gmail.com.
- University of Alabama, Birmingham, USA. abdulkarimghaith@gmail.com.
- The Ohio State University, Columbus, USA.
- University of Alabama, Birmingham, USA.
- University of Arizona, Phoenix, USA.
ORCID-Profile: Abdul Karim Ghaith
Zitieren
APA
Khalilullah, T., Ghaith, A. K., Yang, X., Amatya, B., Wang, X., Fan, L., Momeni, A., Kim, N., Khalifeh, J., Weinberg, J., Azad, T., Xia, Y., Ghandour, M., Belzberg, A., Redmond, K., Alasadi, Y., Butler, D., Patrick, M., Theodore, N., & Lubelski, D. (2026). Comparative outcomes of proton and photon therapy in the management of malignant peripheral nerve sheath tumors. European Spine Journal. https://doi.org/10.1007/s00586-026-10185-y
Vancouver
Khalilullah T, Ghaith AK, Yang X, Amatya B, Wang X, Fan L, et al. Comparative outcomes of proton and photon therapy in the management of malignant peripheral nerve sheath tumors. European Spine Journal. 2026. doi:10.1007/s00586-026-10185-y
BibTeX
@article{Khalilullah2026,
author = {Khalilullah, Taha and Ghaith, Abdul Karim and Yang, Xinlan and Amatya, Bibhas and Wang, Xihang and Fan, Leon and Momeni, Arman and Kim, Nathan and Khalifeh, Jawad and Weinberg, Joshua and Azad, Tej and Xia, Yuanxuan and Ghandour, Maher and Belzberg, Allan and Redmond, Kristin and Alasadi, Yazan and Butler, Danner and Patrick, Madison and Theodore, Nicholas and Lubelski, Daniel},
title = {Comparative outcomes of proton and photon therapy in the management of malignant peripheral nerve sheath tumors},
journal = {European Spine Journal},
year = {2026},
doi = {10.1007/s00586-026-10185-y}
}
EUVIMED